Literature DB >> 29045180

Quantitative Liver MRI-Biopsy Correlation in Pediatric and Young Adult Patients With Nonalcoholic Fatty Liver Disease: Can One Be Used to Predict the Other?

Jonathan R Dillman1, Andrew T Trout1, Emma N Costello2, Suraj D Serai1, Kristin S Bramlage2, Rohit Kohli2,3, Stavra A Xanthakos2.   

Abstract

OBJECTIVE: The purpose of this study is to determine the relationships between quantitative liver MRI measurements and liver biopsy findings in pediatric and young adult patients with nonalcoholic fatty liver disease (NAFLD).
MATERIALS AND METHODS: Data were obtained from a registry that prospectively enrolls pediatric and young adult patients with biopsy-confirmed NAFLD at our tertiary medical center with parent or guardian and subject informed consent, as appropriate. Patients enrolled between November 2007 and June 2016 with a quantitative liver MRI examination within 6 months of biopsy were included (n = 69). Liver stiffness (kilopascals), volume (milliliters), and fat fraction (percentage) were extracted from MRI records. Multiple linear regression was used to determine the relationships between NAFLD activity score and quantitative MRI measures, and between MRI liver stiffness and histopathologic scores (steatosis, lobular inflammation, portal inflammation, hepatocyte ballooning, and fibrosis). Histopathologic data were extracted from medical records, with severity graded by hepatopathologists using Non-alcoholic Steatohepatitis (NASH) Clinical Research Network criteria. Ordinal logistic regression was used to assess the relationship between categoric NAFLD severity (simple steatosis vs NASH vs NASH with significant fibrosis) and MRI measures.
RESULTS: The mean (± SD) patient age at the time of MRI was 14.3 ± 2.8 years (range, 8-21 years); 25 (36.2%) patients were female. Liver biopsy was performed within a mean of 64.4 days of the MRI examination. There was a positive correlation between histopathologic steatosis and MRI liver fat fraction (ρ = 0.57; p < 0.0001). MRI fat fraction was the only significant imaging predictor of NAFLD activity score (p = 0.017). Fibrosis score was the only significant histopathologic predictor of MRI liver stiffness (p = 0.001). MRI liver volume was the only imaging predictor of categoric NAFLD severity (odds ratio = 1.001; 95% CI, 1.000-1.002; p = 0.007).
CONCLUSION: There was significant positive correlation between histopathologic and MRI liver fat measurements in our cohort. MRI liver stiffness did not predict the severity of fatty liver disease in children and young adults.

Entities:  

Keywords:  MRI; biopsy; children; nonalcoholic fatty liver disease; quantitative

Mesh:

Year:  2017        PMID: 29045180      PMCID: PMC6044727          DOI: 10.2214/AJR.17.18446

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  23 in total

1.  Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014.

Authors:  Cynthia L Ogden; Margaret D Carroll; Hannah G Lawman; Cheryl D Fryar; Deanna Kruszon-Moran; Brian K Kit; Katherine M Flegal
Journal:  JAMA       Date:  2016-06-07       Impact factor: 56.272

2.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

3.  Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer; Michael S Middleton; Cynthia Behling; Kimberly P Newton; Hannah I Awai; Melissa N Paiz; Jessica Lam; Jonathan C Hooker; Gavin Hamilton; John Fontanesi; Claude B Sirlin
Journal:  Hepatology       Date:  2015-02-05       Impact factor: 17.425

4.  Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations.

Authors:  Meng Yin; Kevin J Glaser; Jayant A Talwalkar; Jun Chen; Armando Manduca; Richard L Ehman
Journal:  Radiology       Date:  2015-07-08       Impact factor: 11.105

Review 5.  An update on the assessment and management of metabolic syndrome, a growing medical emergency in paediatric populations.

Authors:  Chiara Mameli; Gian Vincenzo Zuccotti; Carla Carnovale; Erica Galli; Pilar Nannini; Davide Cervia; Cristiana Perrotta
Journal:  Pharmacol Res       Date:  2017-01-19       Impact factor: 7.658

6.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

Review 7.  Nonalcoholic fatty liver disease: a challenge for pediatricians.

Authors:  Valerio Nobili; Naim Alkhouri; Anna Alisi; Claudia Della Corte; Emer Fitzpatrick; Massimiliano Raponi; Anil Dhawan
Journal:  JAMA Pediatr       Date:  2015-02       Impact factor: 16.193

8.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

9.  Spin-echo Echo-planar Imaging MR Elastography versus Gradient-echo MR Elastography for Assessment of Liver Stiffness in Children and Young Adults Suspected of Having Liver Disease.

Authors:  Suraj D Serai; Jonathan R Dillman; Andrew T Trout
Journal:  Radiology       Date:  2016-10-10       Impact factor: 11.105

10.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Aynur Unalp; Cynthia E Behling; Joel E Lavine; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

View more
  6 in total

Review 1.  Paediatric gastrointestinal and hepatobiliary radiology: why do we need subspecialists, and what is new?

Authors:  Tom A Watson; Joy Barber; Helen Woodley
Journal:  Pediatr Radiol       Date:  2021-03-20

2.  Comparison of compressed SENSE and SENSE for quantitative liver MRI in children and young adults.

Authors:  Alexander C Boyarko; Jonathan R Dillman; Jean A Tkach; Amol S Pednekar; Andrew T Trout
Journal:  Abdom Radiol (NY)       Date:  2021-04-24

Review 3.  Putting it all together: established and emerging MRI techniques for detecting and measuring liver fibrosis.

Authors:  Suraj D Serai; Andrew T Trout; Alexander Miethke; Eric Diaz; Stavra A Xanthakos; Jonathan R Dillman
Journal:  Pediatr Radiol       Date:  2018-08-04

4.  Liver MR relaxometry at 3T - segmental normal T1 and T2* values in patients without focal or diffuse liver disease and in patients with increased liver fat and elevated liver stiffness.

Authors:  V C Obmann; N Mertineit; C Marx; A Berzigotti; L Ebner; J T Heverhagen; A Christe; A T Huber
Journal:  Sci Rep       Date:  2019-05-30       Impact factor: 4.379

Review 5.  Quantitative Imaging in Pediatric Hepatobiliary Disease.

Authors:  Haesung Yoon; Hyun Joo Shin; Myung Joon Kim; Mi Jung Lee
Journal:  Korean J Radiol       Date:  2019-09       Impact factor: 3.500

6.  Liver intravoxel incoherent motion diffusion-weighted imaging for the assessment of hepatic steatosis and fibrosis in children.

Authors:  Hyun Joo Shin; Haesung Yoon; Myung-Joon Kim; Seok Joo Han; Hong Koh; Seung Kim; Mi-Jung Lee
Journal:  World J Gastroenterol       Date:  2018-07-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.